Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback